Cyprus/Greece/MaltaCyprusGreeceMalta

Immunodrug goes south-east

17.03.2006

Athens/Paris - US-based drug development company Immuno-Designed Molecules (IDM) Inc. signed in February an exclusive licensing and marketing agreement for its cancer drug Junovan (Muramyl Tripeptide Phosphatidylethanolamine) in south eastern Europe with Genesis Pharma, a privately owned Greek pharmaceutical company. Genesis Pharma will distribute Junovan in Greece, Cyprus, Bulgaria, Croatia, Macedonia, Romania and Slovenia.
In exchange, IDM will receive an upfront license fee and milestone payments on reaching certain sales levels in the territory.
Junovan is an immune system stimulant designed to destroy cancer cells by activating macrophages present in the patient. A Phase III trial, the largest ever published in osteosarcoma, has demonstrated improvement in disease-free periods and overall survival among patients with non-metastatic, resectable osteosarcoma, who were treated with Junovan, corresponding to a relative reduction of 25% in the risk of recurrence, and a relative reduction in the risk of death of 30%.
Junovan has received Orphan Drug Status in both the US and the European Union. IDM expects to receive regulatory approval for Junovan in the US and EU in the course of 2007.

Cyprus/Greece/MaltaCyprusGreeceMalta

10.12.2011

Athens – Greek researchers have called on members of the international research community to sensitise their governments to the problems in their country’s research landscape. “The orderly execution of the badly needed reforms...

Cyprus/Greece/MaltaCyprusGreeceMalta

01.10.2011

Athens – The supply of innovative bio­pharmaceuticals to Greek hospitals has broken down. Swiss Roche AG has pulled the plug by stopping delivery of drugs for cancer and other diseases to some state-funded hospitals. Among them...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.06.2011

Athens – The situation in the pharmaceutical market in Greece increasingly looks to be spiralling out of control. According to the Financial Times, the Greek government already appears to be unable to pay healthcare companies...

Cyprus/Greece/MaltaCyprusGreeceMalta

10.07.2010

Athens – The Novo Nordisk Group has restarted sales of its insulin products in Greece. At the beginning of June, the Danish pharmaceutical company had pulled out 17 products – mostly insulin or insulin analogues – after the Greek...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.03.2010

Athens – A EUR2.5m EU research project targeting olfaction in the malaria carrier Anopheles gambiae is to be coordinated by Greek researchers from the Institute of Bio­logy at the Demokritos National Centre of Scientific Research...

Cyprus/Greece/Malta, PolandCyprusGreeceMalta

29.04.2009

Nicosia – Golgi Pharmaceuticals Ltd is strengthening its collaboration with London-based ReGen Therapeutics. The Cypriot firm will produce and package Colostrinin tablets, and expand distribution to Greece and other Balkan...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.04.2009

Athens –The 5th International Biotechnology Forum (IGBF5), which is to be held May 8-9 in Athens, boasts appearances by three Nobel Prize winners. Andrew Schally, Richard Roberts and Sir Peter Mansfield will speak at the opening...

Cyprus/Greece/MaltaCyprusGreeceMalta

16.04.2009

Golgi Pharmaceuticals of Cyprus is strengthening its collaboration with London-based ReGen Therapeutics. Golgi will produce tablets of and package Colostrinin, and expand distribution to Greece and other Balcan countries....

Cyprus/Greece/MaltaCyprusGreeceMalta

03.11.2008

Athens/Houston – Greece is planning to establish state-of-the-art clinics for stem cell therapy with associated stem cell banks. In mid-August, GloCal Investment Ventures Enterprise (G.I.V.E.) – a venture capital fund backed by...

Cyprus/Greece/MaltaCyprusGreeceMalta

18.08.2008

Athens – Greek diagnostics supplier Neo­medica has entered into a distribution agreement with Swedish Life Assays AB (Lund), a daughter of Chemel AB. Neo­medica, a specialist for point-of care tests, now has exclusive rights to...

Displaying results 1 to 10 out of 47

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-cyprus-greece-malta/article/immunodrug-goes-south-east.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products